Calliditas Therapeutics (NASDAQ:CALT) just reported results for the first quarter of 2024.
- Calliditas Therapeutics reported earnings per share of -88 cents. This was below the analyst estimate for EPS of -14 cents.
- The company reported revenue of $28.43 million.
- This was 18.07% worse than the analyst estimate for revenue of $34.70 million.